Cellectis announced on Tuesday evening that the funds obtained from its partner AstraZeneca would help finance its operations until at least 2026.

With the completion of the additional $140 million investment from the pharmaceutical giant, the biotech company had some $143 million in cash on March 31.

The company believes that this capital will be sufficient to finance its operations until 2026.

The genome-editing specialist - which seeks to develop potential therapies for the treatment of serious diseases - reported adjusted consolidated net income attributable to shareholders of $6.5 million (or $0.09 per share) for the first three months of 2024, compared with a net loss of $28.1 million (or a loss of $0.55 per share) for the first three months of 2023.

Consolidated sales and other operating income amounted to $6.5 million for the quarter, compared with $3.6 million for the same period in 2023.

Following this publication, Cellectis shares were little changed (-0.4%) on Wednesday morning on the Paris Bourse. The stock has lost more than 11% since the start of the year, but is up 37% over the last 12 months.

Copyright (c) 2024 CercleFinance.com. All rights reserved.